Gomes J C, Basso S V
Agents Actions. 1986 Apr;18(1-2):191-3. doi: 10.1007/BF01988018.
Histamine release from guinea pig heart treated with compound 48/80 was potentiated by the cyclooxygenase inhibitors indomethacin and piroxicam but not by aspirin or phenylbutazone. This differential effect suggests that the potentiation is not merely due to an inhibition of prostaglandin synthesis. Piroxicam potentiated the histamine release induced by cardiac anaphylaxis whereas indomethacin reduced this effect. The SRS-A antagonist FPL 55712 inhibited histamine release induced by cardiac anaphylaxis, but not that evoked by compound 48/80, and also prevented the potentiation due to indomethacin and piroxicam. In total, these data suggest that the potentiation of histamine release by piroxicam and indomethacin is probably due to a diversion of arachidonic acid metabolism from the cyclooxygenase to the lipoxygenase pathways. The resulting lipoxygenase products may then regulate histamine release, with the secretion due to antigen being more sensitive to such modulation than that evoked by compound 48/80.
用化合物48/80处理豚鼠心脏后,组胺释放可被环氧化酶抑制剂吲哚美辛和吡罗昔康增强,但阿司匹林或保泰松则无此作用。这种差异效应表明,增强作用不仅仅是由于前列腺素合成受到抑制。吡罗昔康增强了心脏过敏反应诱导的组胺释放,而吲哚美辛则降低了这种效应。SRS - A拮抗剂FPL 55712抑制心脏过敏反应诱导的组胺释放,但不抑制化合物48/80诱发的组胺释放,并且还可防止吲哚美辛和吡罗昔康引起的增强作用。总体而言,这些数据表明,吡罗昔康和吲哚美辛对组胺释放的增强作用可能是由于花生四烯酸代谢从环氧化酶途径转向脂氧化酶途径所致。由此产生的脂氧化酶产物可能随后调节组胺释放,与化合物48/80诱发的组胺释放相比,抗原诱导的组胺分泌对这种调节更为敏感。